Professur für Translationale Frauenheilkunde und Geburtshilfe

Universitätsstraße 21/23
91054 Erlangen

Publications (Download BibTeX)

Go to first page Go to previous page 1 of 17 Go to next page Go to last page

Jiang, X., Finucane, H.K., Schumacher, F.R., Schmit, S.L., Tyrer, J.P., Han, Y.,... Lindstrom, S. (2019). Shared heritability and functional enrichment across six solid cancers. Nature Communications, 10(1).
Dork, T., Peterlongo, P., Mannermaa, A., Bolla, M.K., Wang, Q., Dennis, J.,... Geisler, J. (2019). Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 9(1).
Golub, Y., Kuitunen-Paul, S., Panaseth, K., Stonawski, V., Frey, S., Steigleder, R.,... Eichler, A. (2019). Salivary and hair cortisol as biomarkers of emotional and behavioral symptoms in 6–9 year old children. Physiology & behavior, 209.
Hurvitz, S.A., Martin, M., Jung, K.H., Huang, C.S., Harbeck, N., Valero, V.,... Slamon, D. (2019). Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2–positive breast cancer: Three-year outcomes from the phase III KristinE study. Journal of Clinical Oncology, 37(25), 2206-2216.
Untch, M., Jackisch, C., Schneeweiss, A., Schmatloch, S., Aktas, B., Denkert, C.,... Loibl, S. (2019). Nab-paclitaxel improves disease-free survival in early breast cancer: GBG 69–Geparsepto. Journal of Clinical Oncology, 37(25), 2226-2234.

Wallwiener, M., Nabieva, N., Feisst, M., Fehm, T., De Waal, J., Rezai, M.,... Fasching, P. (2019). Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer, 19.
Mamounas, E.P., Geyer, C.E., Huang, C.-S., Mano, M.S., Loibl, S., Untch, M.,... Von Minckwitz, G. (2019). KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. In SWISS MEDICAL WEEKLY (pp. 13S-13S). MUTTENZ: E M H SWISS MEDICAL PUBLISHERS LTD.
Mavratzas, A., Baek, S., Gerber, B., Schmidt, M., Moebus, ., Foerster, F.,... Marine, F. (2019). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. BREAST , 45, 22-28.
Noske, A., Möbus, V., Weber, K., Schmatloch, S., Weichert, W., Köhne, C.H.,... Denkert, C. (2019). Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study. European journal of cancer, 114, 76-88.
Ooi, B.N.S., Loh, H., Ho, P.J., Milne, R.L., Giles, G., Gao, C.,... Li, J. (2019). The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 48(3), 781-794.
Vachon, C.M., Scott, C.G., Tamimi, R.M., Thompson, D.J., Fasching, P., Stone, J.,... Garcia-Closas, M. (2019). Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk. Breast Cancer Research, 21.
Laakmann, E., Witzel, I., Fasching, P., Rezai, M., Schem, C., Solbach, C.,... Loibl, S. (2019). Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. Breast Cancer Research, 21(1).
Huang, M., Qi, C.Z., Ramsey, S., Briggs, A., Zhao, J., Haiderali, A.,... Fasching, P. (2019). Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy. In ANNALS OF ONCOLOGY (pp. 34-+). Berlin, DE: OXFORD: OXFORD UNIV PRESS.
Jank, P., Loibl, S., Fasching, P., Karn, T., Marme, F., Mueller, V.,... Denkert, C. (2019). Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials. In ANNALS OF ONCOLOGY. Berlin, DE: OXFORD: OXFORD UNIV PRESS.
Fasching, P., Quek, R.G.W., Bhattacharyya, H., Hurvitz, S.A., Rugo, H.S., & Ettl, J. (2019). Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial. In ANNALS OF ONCOLOGY. Berlin, DE: OXFORD: OXFORD UNIV PRESS.
Turner, N.C., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E.-M.,... Robson, M.E. (2019). A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research, 25(9), 2717-2724.
Ferreira, M.A., Gamazon, E.R., Al-Ejeh, F., Aittomaki, K., Andrulis, I.L., Anton-Culver, H.,... Yip, D. (2019). Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 10.
Wunderle, M., Pretscher, J., Brucker, S.Y., Volz, B., Hartmann, A., Fiessler, C.,... Rauh, C. (2019). Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 174(2), 453-461.
Deniz, M., Degregorio, A., Degregorio, N., Bekes, I., Widschwendter, P., Schochter, F.,... Friedl, T.W.P. (2019). Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. BREAST , 44, 81-89.

Last updated on 2019-24-04 at 10:28